{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026900","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.608669+00:00","generated_at":"2026-06-21T23:07:23.291973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin reports Q3 2022 net loss of $22.3M for nine months; cash $50.4M sufficient beyond mid-2024","bullets":["R&D expense $14.8M (nine months) vs $11.2M YoY; net loss $22.3M vs $13.1M.","Cash $50.4M, sufficient beyond mid-2024; operating cash burn $20.4M.","Three Phase 1/2 trials for Annamycin active; no cardiotoxicity in 42 subjects.","WP1066 pediatric brain tumor trial enrolled final subject in Phase 1 at 8 mg/kg.","WP1122 received FDA Orphan Drug for GBM; Phase 1a completed; WP1096 selected for NIH studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026900","json":"https://secwatch.observer/filing/0001437749-22-026900.json","markdown":"https://secwatch.observer/filing/0001437749-22-026900.md","text":"https://secwatch.observer/filing/0001437749-22-026900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/0001437749-22-026900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/mbrx20221107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:07:23.291973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ead307d8006ce567f8f88aba24be859a40fbc5f5","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/0001437749-22-026900-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}